From retail to restaurants, "Mad Money" host Jim Cramer is naming his top buys in the wake of the Dow hitting 18K.» Read More
Express Scripts said Monday that it will no longer cover Sovaldi and Harvoni— two Gilead Sciences drugs that cost more than $80,000 each for a full course of treatment— or Johnson& Johnson's Olysio starting Jan. 1, except under limited circumstances. Instead, it will make AbbVie Inc.' s Viekira Pak, approved only Friday, the preferred treatment for patients who have...
Dec 22- Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies. The first study, testing a combination of 50 mg of Achillion's ACH-3102 and 400 mg of Gilead Sciences Inc's Sovaldi, showed the regimen sustained a cure in patients for four weeks...
*Gilead falls as Express Scripts chooses AbbVie treatment. NEW YORK, Dec 22- U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, as oil prices continued to show signs of stabilizing. However, Brent pulled back to last trade down 14 cents to $61.24 while U.S. crude was last off 0.4 percent at $56.91.
Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading. The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline...
Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12- week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences. AbbVie's newly approved regimen is also less costly than Gilead's newest one-pill regimen that combines Sovaldi with...
Amgen Inc. rose $1.69 or 1.0 percent, to $170.17. Biogen Idec rose $6.97 or 2.0 percent, to $360.67. Celgene Corp. rose$. 70 or. 6 percent, to $117.18.
TRENTON, N.J.— Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie. The Food and Drug Administration on Friday approved the sale of a packaged treatment called Viekira Pak made by AbbVie Inc. of North Chicago, Illinois. It includes a combination pill, which...
Dec 19- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.
Amgen Inc. rose$. 07 or percent, to $168.55. Biogen Idec rose $4.57 or 1.3 percent, to $358.27. Celgene Corp. rose$. 44 or. 4 percent, to $116.92.
American Realty Capital Properties Inc. fell. 6 percent to $8.02 with 28,386,500 shares traded. Apple Inc. fell. 8 percent to $111.78 with 75,717,300 shares traded. BlackBerry Ltd. fell. 8 percent to $9.99 with 30,981,500 shares traded.
Amgen Inc. fell$. 37 or. 2 percent, to $168.11. Biogen Idec fell $3.70 or 1.0 percent, to $350.00. Celgene Corp. rose$. 12 or. 1 percent, to $116.60.
Amgen Inc. rose $5.00 or 3.1 percent, to $168.48. Biogen Idec rose $20.81 or 6.3 percent, to $353.70. Celgene Corp. rose $3.66 or 3.2 percent, to $116.48.
Jim Cramer is seeing some good signs in the economy right now. Could they be the perfect ingredients for a Santa Claus rally?
Amgen Inc. rose $3.32 or 2.0 percent, to $166.80. Biogen Idec rose $15.05 or 4.5 percent, to $347.94. Celgene Corp. rose $2.68 or 2.4 percent, to $115.50.
Amgen Inc. rose $2.18 or 1.3 percent, to $165.66. Biogen Idec rose $12.84 or 3.9 percent, to $345.73. Celgene Corp. rose $2.63 or 2.3 percent, to $115.45.
Amgen Inc. rose $4.04 or 2.5 percent, to $163.48. Biogen Idec rose $7.76 or 2.4 percent, to $332.89. Celgene Corp. rose $2.73 or 2.5 percent, to $112.82.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Amgen Inc. rose $1.41 or. 9 percent, to $160.85. Biogen Idec rose $2.00 or. 6 percent, to $327.13. Celgene Corp. rose$. 63 or. 6 percent, to $110.72.
Amgen Inc. rose $1.19 or. 7 percent, to $160.63. Biogen Idec fell$. 02 or percent, to $325.11. Celgene Corp. rose$. 26 or. 2 percent, to $110.35.
Amgen Inc. fell$. 16 or. 1 percent, to $159.44. Biogen Idec fell $10.67 or 3.2 percent, to $325.13. Celgene Corp. fell $1.79 or 1.6 percent, to $110.09.